Select Page
Promising Pathway Act

The Promising Pathway Act reintroduced in the Senate on May 13, 2021 will expedite beneficial outcomes for patients by requiring the Food and Drug Administration (FDA) to establish a rolling, real-time, priority review pathway for drugs intended to treat, prevent, or diagnose serious or life-threatening diseases or conditions.

Media Contact: Theresa Garner, theresa@iamals.org

Promising Pathway Act 2021 Updates

Promising Pathway Act 2020 Updates

More information

Contact your congresspeople about the Promising Pathway Act 2.0